Immediate Impact
1 from Science/Nature 68 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Lung cancer statistics, 2023
2024 Standout
Works of Takeo Endo being referenced
Epidermal Growth Factor Receptor Mutations: Effect on Volume Doubling Time of Non–Small-Cell Lung Cancer Patients
2014
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Takeo Endo | 252 | 214 | 35 | 107 | 24 | 397 | |
| Kenta Kambara | 156 | 157 | 35 | 107 | 35 | 435 | |
| Simone Hummler | 211 | 184 | 14 | 144 | 16 | 408 | |
| S. Zonato | 123 | 173 | 53 | 88 | 21 | 361 | |
| Willemieke P.M. Dijksterhuis | 203 | 168 | 193 | 111 | 30 | 443 | |
| Maiko Kadowaki | 165 | 46 | 24 | 46 | 19 | 336 | |
| Alexander Emmert | 130 | 98 | 92 | 77 | 27 | 384 | |
| Stefania Vecchio | 179 | 157 | 130 | 64 | 28 | 430 | |
| Weiteng Zhang | 147 | 118 | 145 | 227 | 38 | 423 | |
| Kentaro Masuhiro | 78 | 133 | 17 | 89 | 21 | 358 | |
| P. Zamora | 120 | 251 | 66 | 49 | 25 | 390 |
All Works
Loading papers...